Acute Myeloid Leukemia (AML) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036

Acute Myeloid Leukemia Market Outlook and Forecast

Thelansis's "Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Myeloid Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by clonal expansion of abnormal myeloid precursors that disrupt blood-cell production. Patients may develop cytopenias, infection, and bleeding, with prognosis shaped by age, fitness, molecular features, and measurable residual disease. Treatment ranges from intensive induction chemotherapy to regimens such as azacitidine or decitabine with venetoclax, followed by consolidation or allogeneic stem-cell transplantation in selected patients. Targeted therapy includes FLT3, IDH1/2, and menin-directed agents. Revumenib and ziftomenib are FDA-approved for relapsed/refractory NPM1-mutated AML, while revumenib is approved for KMT2A-translocated acute leukemia. In 2026 oral decitabine/cedazuridine plus venetoclax was approved for newly diagnosed patients unable to receive intensive induction. Priorities include measurable residual disease, resistance, relapse prevention, and durable remission with lower toxicity.

Key Highlights

• In Spain, AML incidence cases are projected to remain broadly stable, from 2,380 in 2026 to 2,368 by 2036.
• AML is an aggressive hematologic malignancy characterized by rapid disease progression and substantial mortality risk.
• Despite advances in targeted therapies and combination regimens, relapse and treatment resistance remain major challenges.
• Significant unmet need remains for therapies that improve durable remission and long-term survival.

Market Overview

• The Germany AML market is projected to grow from $305M in 2026 to $690M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies and novel combination regimens
• Continued development of next-generation AML treatments
• Future growth will depend on therapies that overcome treatment resistance and deliver durable clinical responses.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Syndax Pharmaceuticals
• Ipsen
• Hikma Pharmaceuticals LLC
• Moleculin Biotech, Inc.
• Janssen Research & Development, LLC
• Hutchmed
• AbbVie
• Bristol-Myers Squibb
• Akeso
• Novartis Pharmaceuticals
• PrECOG, LLC.
• Allotera Therapeutics
• Taiho Oncology, Inc.
• OncoVerity, Inc.
• PedAL BCU, LLC
• Daiichi Sankyo Co., Ltd.
• Actinium Pharmaceuticals
• Celgene
• AstraZeneca
• Boehringer Ingelheim
• Astellas Pharma Inc.
• Amphista Therapeutics Ltd
• Pfizer
• Kyowa Kirin Co., Ltd.
• Oryzon Genomics S.A.
• Aptevo Therapeutics
• Charm Therapeutics
• Takeda
• Cullinan Therapeutics Inc.
• Kura Oncology, Inc.
• GluBio Therapeutics Inc.
• Solu Therapeutics, Inc.
• Crossbow Therapeutics, Inc.
• Remix Therapeutics
• Aprea Therapeutics
• Auron Therapeutics, Inc.
• BeOne Medicines
• NovaOnco Therapeutics Co., Ltd.
• Rigel Pharmaceuticals
• Aptose Biosciences Inc.
• Eli Lilly and Company
• Aspera Biomedicines, Inc.